Brain-Computer Interfaces — sector dashboard · fobi

Sign in Sign up free

Funding & analysis

Company

15

16

17

18

19

20

21

22

23

24

25

26

Total Raised

Round sizes
Median round size surged in 2025–2026. Mega-rounds ($200M+) dominated: Neuralink Series E ($650M), BrainCo Series B+ ($286M), Science Corporation Series C ($230M), Synchron Series D ($200M). Early-stage median remains modest ($10–20M), but mega-rounds pulled average sharply upward.
Stage mix
Late-stage capital overwhelmingly concentrated. Series C/D/E and growth rounds comprise 60% of 2025–2026 volume by value. IPO exits (Saluda, Ceribell) and strategic acquisitions (Nalu $533M) signaled maturation. Seed activity steady but small ($2–17M per round). Few Series A/B rounds relative to mega-rounds.
Lead investors
Khosla Ventures led multiple tranches across Science Corporation and Flow Neuroscience, cementing dominance. ARK Invest, Sequoia, Founders Fund co-led Neuralink's $650M round. Novo, Boston Scientific, IDG Capital led late-stage cheques. Golden Falcon Capital emerged as early-stage repeat backer (Subsense). Traditional VCs quiet; strategic acquirers and mega-funds reshaped cap table.